Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCO-101 with Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
NCT04652206Phase 2Unknown
- Sponsor
- Scandion Oncology
- Start
- Oct 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of sco-101 in pancreatic adenocarcinoma (PDAC), sponsored by Scandion Oncology. Status: unknown.
02
Drugs
sco-101
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04652206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04652206.